8-K: Biora Therapeutics Announces Positive Supplemental Data from BT-600 Phase 1 Trial, Demonstrating Targeted Drug Delivery to Colon

Biora Therapeutics' BT-600 Phase 1 trial shows successful targeted drug delivery to the colon using the NaviCap device, with lower systemic exposure and promising tissue concentrations.

Summary

• Biora Therapeutics announced supplemental data from its Phase 1 clinical trial of BT-600, an orally administered drug-device combination for ulcerative colitis.
• The trial used the NaviCap device to deliver a liquid formulation of tofacitinib directly to the colon.
• Results showed a pharmacokinetic profile consistent with drug delivery and absorption in the colon for both single and multiple ascending dose cohorts.
• Systemic absorption of tofacitinib was first observed at six hours, indicating colonic delivery, with maximal levels at eight to ten hours, compared to 30 minutes for conventional oral tofacitinib.
• Maximal systemic drug exposure was three to four times lower than with conventional oral tofacitinib, demonstrating the NaviCap's ability to limit systemic exposure.
• Tissue biopsies confirmed drug exposure extending to the distal colon, with modeling projecting tissue levels above the estimated IC90 for at least 16 hours after dosing.
• Post-retrieval device analysis confirmed accurate drug delivery in the colon, with over 95% of devices detecting colon entry and no early release.
• The NaviCap devices were well tolerated, with all adverse events being mild and consistent with those expected in a healthy population.
• Mean tissue concentrations in the splenic flexure, descending colon, and sigmoid colon were above the established IC50 for the JAK-STAT pathway at 24 hours.
• A strong correlation was found between tissue and plasma levels, allowing for modeling of tissue levels at earlier time points.

Sentiment

Score: 8

Explanation: The document presents very positive results from the Phase 1 trial, indicating a significant advancement in targeted drug delivery. The data supports the potential of the NaviCap platform and BT-600, leading to a high sentiment score.

Positives

• The NaviCap device successfully delivered tofacitinib directly to the colon, achieving targeted drug delivery.
• The trial showed lower systemic drug exposure compared to conventional oral tofacitinib, potentially reducing toxicity risks.
• The drug was distributed throughout the colon, reaching distal sites of disease.
• The device was well-tolerated by participants, with no significant safety concerns.
• The study provides evidence that the NaviCap platform can deliver other molecules and drug classes in UC and beyond.
• The results support the advancement of BT-600 into clinical trials for UC patients.

Negatives

• The study was conducted in healthy participants, not in patients with ulcerative colitis.
• The study used a relatively small sample size of 48 healthy participants.
• The long-term efficacy and safety of BT-600 in UC patients are yet to be determined.
• The study used 5mg and 10mg doses of tofacitinib, which are 50-75% lower than approved doses for conventional tofacitinib, and the efficacy of these lower doses needs to be confirmed in UC patients.

Risks

• The success of BT-600 in future clinical trials is not guaranteed.
• Regulatory approval for BT-600 is not assured.
• The company faces competition from other companies developing treatments for ulcerative colitis.
• The company's ability to raise sufficient capital to achieve its business objectives is a risk.
• There are risks related to the supply and manufacturing of the NaviCap devices.

Future Outlook

Biora Therapeutics plans to move into a clinical trial in UC patients, with a Phase 1b trial planned to start in Q4 2024 and a Phase 2 trial planned to start in Q4 2025.

Management Comments

• Ariella Kelman, MD, Chief Medical Officer of Biora Therapeutics, stated that they are excited by the colon tissue drug exposure seen in the trial and that the model projects tissue levels well above IC90 through at least 16 hours post dose.
• Adi Mohanty, Chief Executive Officer of Biora Therapeutics, stated that they plan to break through the therapeutic ceiling in UC by changing the way gastrointestinal diseases are treated with their NaviCap platform.

Industry Context

The announcement is relevant to the broader industry trend of developing targeted drug delivery systems to improve efficacy and reduce side effects of treatments for inflammatory bowel diseases. The NaviCap platform aims to address the limitations of current treatments by delivering drugs directly to the colon, potentially improving patient outcomes.

Comparison to Industry Standards

• Conventional oral tofacitinib reaches maximal systemic levels in 30 minutes, while BT-600 reached maximal levels in 8-10 hours, indicating successful colonic delivery.
• Maximal systemic drug exposure with BT-600 was three to four times lower than with conventional oral tofacitinib, suggesting reduced systemic side effects.
• The study showed that BT-600 achieved tissue concentrations above the IC50 at 24 hours, which is comparable to or better than some existing treatments.
• The NaviCap device's >95% success rate in detecting colon entry is a significant improvement over other colonic delivery methods that often have variable delivery rates.

Stakeholder Impact

• Shareholders may view the positive trial results as a positive development for the company's future prospects.
• Employees may be encouraged by the progress of the company's research and development efforts.
• Patients with ulcerative colitis may benefit from the development of a more effective and targeted treatment option.
• Potential partners may be interested in collaborating with Biora Therapeutics on the development of the NaviCap platform.

Next Steps

• Biora Therapeutics plans to initiate a Phase 1b clinical trial in UC patients in Q4 2024.
• A Phase 2 clinical trial in UC patients is planned to start in Q4 2025.

Key Dates

Keywords

ulcerative colitis, BT-600, NaviCap, tofacitinib, targeted drug delivery, colonic delivery, pharmacokinetics, clinical trial, inflammatory bowel disease, drug-device combination